Eris Lifesciences Ltd

Company Profile

Eris Lifesciences Ltd had its IPO on under the ticker symbol ERIS.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Eris Lifesciences Ltd has a staff strength of 0 employees.

Stock update

Shares of Eris Lifesciences Ltd opened at ₹812.05 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹791.55 - ₹819.45, and closed at ₹807.85.

This is a -0.97% slip from the previous day's closing price.

A total volume of 12,639 shares were traded at the close of the day’s session.

In the last one week, shares of Eris Lifesciences Ltd have increased by +0.3%.

Eris Lifesciences Ltd's Key Ratios

Eris Lifesciences Ltd has a market cap of ₹111.09 billion, indicating a price to book ratio of 4.5458 and a price to sales ratio of 6.241.

In the last 12-months Eris Lifesciences Ltd’s revenue was ₹17.30 billion with a gross profit of ₹13.44 billion and an EBITDA of ₹5.75 billion. The EBITDA ratio measures Eris Lifesciences Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Eris Lifesciences Ltd’s operating margin was 25.6% while its return on assets stood at 8.83% with a return of equity of 18.12%.

In Q2, Eris Lifesciences Ltd’s quarterly earnings growth was a positive 0.3% while revenue growth was a positive 17.3%.

Eris Lifesciences Ltd’s PE and PEG Ratio

Forward PE

18.6916

Trailing PE

29.0676

PEG

Its diluted EPS in the last 12-months stands at ₹28.1 per share while it has a forward price to earnings multiple of 18.6916 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eris Lifesciences Ltd’s profitability.

Eris Lifesciences Ltd stock is trading at a EV to sales ratio of 6.3695 and a EV to EBITDA ratio of 18.0718. Its price to sales ratio in the trailing 12-months stood at 6.241.

Eris Lifesciences Ltd stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 26.17%.

Balance sheet and cash flow metrics

Total Assets

₹36.67 billion

Total Liabilities

₹4.43 billion

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

26.17%

Eris Lifesciences Ltd ended 2024 with ₹36.67 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹36.67 billion while shareholder equity stood at ₹21.96 billion.

Eris Lifesciences Ltd ended 2024 with ₹0 in deferred long-term liabilities, ₹4.43 billion in other current liabilities, 135990000.00 in common stock, ₹21.82 billion in retained earnings and ₹3.32 billion in goodwill. Its cash balance stood at ₹560.22 million and cash and short-term investments were ₹868.08 million. The company’s total short-term debt was ₹1,855,690,000 while long-term debt stood at ₹6.44 billion.

Eris Lifesciences Ltd’s total current assets stands at ₹7.65 billion while long-term investments were ₹0 and short-term investments were ₹307.86 million. Its net receivables were ₹2.93 billion compared to accounts payable of ₹1.25 billion and inventory worth ₹1.31 billion.

In 2024, Eris Lifesciences Ltd's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Eris Lifesciences Ltd paid ₹0.26 in dividends in 2024.

Other key metrics

Current Trading Price

₹807.85

52-Week High

₹845

52-Week Low

₹550.9

Analyst Target Price

₹

Eris Lifesciences Ltd stock is currently trading at ₹807.85 per share. It touched a 52-week high of ₹845 and a 52-week low of ₹845. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹783.44 and 200-day moving average was ₹671.92 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 8104.9% of the company’s stock are held by insiders while 1493.7% are held by institutions.